Skip to main content

Opiod Use Disorder

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
ANS-6637Phase 11 trial
Active Trials
NCT03831971Completed26Est. Dec 2019
Delpor
DelporCA - Brisbane
1 program
Combination Product: NaltrexonePHASE_11 trial
Active Trials
NCT05304364Completed10Est. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
DelporCombination Product: Naltrexone
Allergy TherapeuticsANS-6637

Clinical Trials (2)

Total enrollment: 36 patients across 2 trials

NCT05304364DelporCombination Product: Naltrexone

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

Start: Mar 2022Est. completion: Nov 202210 patients
Phase 1Completed

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

Start: Mar 2019Est. completion: Dec 201926 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.